Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
VolitionRx (NYSE AMERICAN: VNRX) has expanded its Nu.Q® Vet Cancer Test supply agreement with Fujifilm Vet Systems in Japan. The new five-year agreement includes Volition's chemiluminescent immunoassay (ChLIA) version via the IDS i10® automated analyzer platform.
The expansion builds upon the previous agreement that offered the manual ELISA format test. Fujifilm Vet Systems plans to launch the automated platform for canine cancer screening in summer 2025, following final validation and verification. Since the initial launch in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test.
The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test through its network of central reference laboratories in Japan, targeting a market of approximately seven million pet dogs.
VolitionRx (NYSE AMERICAN: VNRX) ha ampliato il suo accordo di fornitura del test Nu.Q® Vet Cancer con Fujifilm Vet Systems in Giappone. Il nuovo accordo quinquennale include la versione chemiluminescente immunoassay (ChLIA) di Volition tramite la piattaforma di analizzatori automatizzati IDS i10®.
L'espansione si basa sull'accordo precedente che offriva il test in formato ELISA manuale. Fujifilm Vet Systems prevede di lanciare la piattaforma automatizzata per lo screening del cancro nei cani nell'estate del 2025, dopo la validazione e la verifica finale. Dall'inizio del lancio nel luglio 2024, oltre 1.000 ospedali veterinari in Giappone si sono registrati per utilizzare il test.
L'accordo consente a Fujifilm Vet Systems di vendere e eseguire il test Nu.Q® Vet Cancer attraverso la sua rete di laboratori di riferimento centrali in Giappone, mirando a un mercato di circa sette milioni di cani domestici.
VolitionRx (NYSE AMERICAN: VNRX) ha ampliado su acuerdo de suministro de la prueba Nu.Q® Vet Cancer con Fujifilm Vet Systems en Japón. El nuevo acuerdo de cinco años incluye la versión de inmunoensayo quimioluminiscente (ChLIA) de Volition a través de la plataforma de analizador automatizado IDS i10®.
La expansión se basa en el acuerdo anterior que ofrecía el test en formato ELISA manual. Fujifilm Vet Systems planea lanzar la plataforma automatizada para el cribado de cáncer en perros en el verano de 2025, tras la validación y verificación final. Desde el lanzamiento inicial en julio de 2024, más de 1,000 hospitales veterinarios en Japón se han registrado para utilizar la prueba.
El acuerdo permite a Fujifilm Vet Systems vender y realizar la prueba Nu.Q® Vet Cancer a través de su red de laboratorios de referencia centrales en Japón, apuntando a un mercado de aproximadamente siete millones de perros de compañía.
VolitionRx (NYSE AMERICAN: VNRX)는 일본의 Fujifilm Vet Systems와 Nu.Q® Vet Cancer Test 공급 계약을 확대했습니다. 새로운 5년 계약에는 IDS i10® 자동 분석기 플랫폼을 통한 Volition의 화학발광 면역측정법(ChLIA) 버전이 포함됩니다.
이번 확장은 수동 ELISA 형식 테스트를 제공했던 이전 계약을 기반으로 합니다. Fujifilm Vet Systems는 최종 검증 및 확인 후 2025년 여름에 개 암 진단을 위한 자동화된 플랫폼을 출시할 계획입니다. 2024년 7월 최초 출시 이후 일본의 1,000개 이상의 수의 병원이 이 테스트를 사용하기 위해 등록했습니다.
이 계약은 Fujifilm Vet Systems가 일본의 중앙 참조 실험실 네트워크를 통해 Nu.Q® Vet Cancer Test를 판매하고 수행할 수 있도록 하며, 약 700만 마리의 반려견 시장을 목표로 하고 있습니다.
VolitionRx (NYSE AMERICAN: VNRX) a élargi son accord de fourniture du test Nu.Q® Vet Cancer avec Fujifilm Vet Systems au Japon. Le nouvel accord de cinq ans comprend la version de l'immunoessai chimiluminescent (ChLIA) de Volition via la plateforme d'analyse automatisée IDS i10®.
Cette expansion s'appuie sur l'accord précédent qui offrait le test au format ELISA manuel. Fujifilm Vet Systems prévoit de lancer la plateforme automatisée pour le dépistage du cancer chez les chiens à l'été 2025, après validation et vérification finales. Depuis le lancement initial en juillet 2024, plus de 1 000 hôpitaux vétérinaires au Japon se sont inscrits pour utiliser le test.
L'accord permet à Fujifilm Vet Systems de vendre et de réaliser le test Nu.Q® Vet Cancer par le biais de son réseau de laboratoires de référence centraux au Japon, visant un marché d'environ sept millions de chiens de compagnie.
VolitionRx (NYSE AMERICAN: VNRX) hat seine Liefervereinbarung für den Nu.Q® Vet Cancer Test mit Fujifilm Vet Systems in Japan erweitert. Die neue fünfjährige Vereinbarung umfasst die chemilumineszente Immunoassay-Version (ChLIA) von Volition über die automatisierte Analyseplattform IDS i10®.
Die Erweiterung baut auf der vorherigen Vereinbarung auf, die den manuellen ELISA-Test anbot. Fujifilm Vet Systems plant, die automatisierte Plattform für das Screening von Krebs bei Hunden im Sommer 2025 nach der endgültigen Validierung und Überprüfung einzuführen. Seit dem ursprünglichen Start im Juli 2024 haben sich über 1.000 Tierkliniken in Japan registriert, um den Test zu verwenden.
Die Vereinbarung erlaubt es Fujifilm Vet Systems, den Nu.Q® Vet Cancer Test über sein Netzwerk von zentralen Referenzlaboren in Japan zu verkaufen und durchzuführen, wobei ein Markt von etwa sieben Millionen Haustierhunden angestrebt wird.
- Over 1,000 veterinary hospitals in Japan already registered to use the test
- Access to market of 7 million pet dogs in Japan
- Automation upgrade will enable higher throughput and faster turnaround
- Five-year agreement extension with leading Japanese diagnostic provider
- Platform still requires final validation and verification before launch
Insights
The expansion of the Nu.Q® Vet Cancer Test to an automated platform represents a significant advancement in veterinary oncology diagnostics. The transition from manual ELISA to automated ChLIA testing addresses critical workflow barriers in busy veterinary practices, typically yielding 3-5x throughput improvement while reducing hands-on technician time. This automation should substantially improve testing scalability and turnaround times.
The rapid adoption by over 1,000 veterinary hospitals in Japan since the July 2024 launch demonstrates impressive market validation. With approximately 7 million pet dogs in Japan, and cancer being the leading cause of adult canine deaths, the addressable market is substantial.
This centralized lab automation model aligns perfectly with Japan's sophisticated veterinary infrastructure, where reference laboratories are well-integrated into clinical workflows. The IDS i10® analyzer platform is already established in clinical diagnostics, which minimizes implementation challenges.
The five-year agreement term provides stability for market development and suggests confidence from both parties in the commercial potential. This partnership with Fujifilm Vet Systems, a leading diagnostic provider in Japan, leverages existing distribution channels and laboratory infrastructure, allowing Volition to expand market presence without direct infrastructure investment.
This agreement expansion represents meaningful commercial progress for Volition's veterinary diagnostics strategy. The transition to an automated platform addresses scalability challenges inherent in manual ELISA testing and should improve operating margins through increased throughput and reduced labor costs.
Japan represents an ideal market for premium veterinary diagnostics with high pet insurance penetration (approximately 40% compared to 1-2% in many Western markets) and sophisticated veterinary care infrastructure. The rapid adoption by 1,000+ veterinary hospitals in just 8 months indicates strong market acceptance.
The shared technology platform approach across both veterinary and human applications demonstrates operational efficiency that should favorably impact R&D allocation and manufacturing economics. This technology commonality could accelerate improvements across both market segments.
For a company with a
While the planned Summer 2025 launch means revenue impact is not immediate, this agreement provides a foundation for sustainable growth in the veterinary diagnostics segment and potentially validates the underlying technology for human applications.
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition added:
"There are approximately seven million pet dogs in
"We are delighted to have extended our agreement with Fujifilm Vet Systems to include our automated platform. This will greatly facilitate the increased demand with rapid turn around."
Kiyotaka Fujiwara, Chief Operating Officer at Fujifilm Vet Systems, said:
"Since our launch of the Nu.Q® Vet Cancer Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, indeed the number of veterinary hospitals registered to use the test in
Dr. Jasmine Kway, added:
"Cancer is the leading cause of adult canine deaths; earlier detection can improve outcomes. The Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs to aid in early cancer detection.
"This automated central lab platform is the same platform Volition utilizes for its human products, Nu.Q® Cancer, Nu.Q® NETs and Nu.Q® Discover demonstrating the synergy across the Nu.Q® technology platform."
Volition's supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test throughout its network of central reference laboratories in
About the Nu.Q® Vet Cancer Test
The Nu.Q® Vet Cancer Test is intended for use during regular preventive check-ups of older dogs (seven years and older) or for younger dogs of high-risk breeds. At a global average price per test of
About FujiFilm Vet Systems
FujiFilm Vet Systems is a subsidiary of FujiFilm Holdings Corporation, listed on the
FujiFilm Vet Systems provides testing services centered on health checkups to veterinary medical facilities nationwide with relationships throughout the estimated 11,000 veterinary medical facilities in
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-signs-first-ever-nuq-vet-cancer-test-automation-agreement-with-fujifilm-vet-systems-302401002.html
SOURCE VolitionRx Limited
FAQ
When will Volition's automated Nu.Q® Vet Cancer Test launch in Japan?
How many veterinary hospitals in Japan are using VNRX's Nu.Q® Vet Cancer Test?
What is the market size for VNRX's Nu.Q® Vet Cancer Test in Japan?
What improvements does the new automated Nu.Q® Vet Cancer Test offer?
How long is VNRX's new supply agreement with Fujifilm Vet Systems?
